Navigation Links
Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
Date:2/18/2009

ISELIN, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some follow on molecules. These CB2-selective cannabinoids are synthetic compounds which belong to the class of nonclassical cannabinoids and thus display fewer of the undesired psychotropic and cardiovascular side-effects seen with some natural cannabinoids.

Pharmos had developed these compounds in preclinical testing for neuropathic pain. The particular patents and know how subject to this agreement share some of the pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, the compounds sold are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents.

The two companies have executed an Asset Purchase Agreement, which is targeted to close on or before June 6, 2009. As well as customary closing conditions, Reperio must reach consent with the Office of the Chief Scientist to clearly define the assumption of potential liabilities for grant payments that were made to Pharmos during the development of the CB2 program.

The sale is consistent with Pharmos' objectives to conserve its cash resources for the development of Dextofisopam, currently enrolling in a Phase 2b US trial. The Company previously announced the closure of its operations in Israel, effective October 31, 2008.

Two of the Company's former scientists will join Reperio and the arrangement allows for further development of these CB2 assets. As part of the agreement Pharmos will be granted an equity ownership in Reperio and will be entitle
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmos Corporation Announces That it Will Cease Operations in Israel
2. Pharmos Corporation Reports 2008 Second Quarter Results
3. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Pharmos Corporation Reports 2008 First Quarter Results
5. Pharmos Corporation Completes Initial Closing of Private Placement
6. Pharmos Corporation Announces Board and Management Changes
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
9. Pharmos Corporation Reports 2007 Third Quarter Results
10. Pharmos Issues Letter to Shareholders
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
(Date:12/24/2014)... December 23, 2014 The report ... its definition, classification, application and industry overview. This ... product cost structure. Production is separated by regions, ... raw materials, equipment, downstream client survey, marketing channels, ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to grow ... data about the vital drivers, restraints, trends, opportunities, strategies and ... http://bit.ly/1yUxy0T , According to the report, the global ... impressive CAGR during near future. It expects this growth to ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... ROCKVILLE, Md., March 17 Novavax, Inc. (Nasdaq: ... fourth quarter financial results in a press release to be ... The Company will hold an investor conference call to discuss ... 30, 2009. The call will be hosted by Novavax President ...
... /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading ... announced financial and operational results for the year ended ... to safely affect MS progression in previous studies and ... trial (MAESTRO-01) in the second half of this year," ...
... Magellan Biosciences, an emerging leader in systems for ... North American Product Innovation Award for LeadCare II, ... adults to be screened for lead poisoning faster, ... Diagnostics, James Whelan, will accept the award tomorrow ...
Cached Biology Technology:Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning 2Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning 3Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning 4
(Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... in a blood vessel from inside that vesselis ... injuries from high-speed collisions or falls (together referred to ... lives and nearly eliminate paraplegia (the loss of the ... of surgical repair for thoracic aortic aneurysms. "Analysis ...
... of America will hold its 93rd annual meeting on ... was founded in 1915 to promote the practice and ... highlight the interdisciplinary nature of ecology and linking research ... research will be presented at the meeting, including a ...
... guerrilla war against the human immune system for eons, but ... has exposed one of the tricks malaria uses to ... drug development. , Malaria parasites (plasmodia) are transmitted to people ... first set up shop in liver cells, then move into ...
Cached Biology News:Stent grafts: a better way to treat blunt trauma injuries 2ESA to feature wide range of UW-Madison presentations 2ESA to feature wide range of UW-Madison presentations 3ESA to feature wide range of UW-Madison presentations 4ESA to feature wide range of UW-Madison presentations 5ESA to feature wide range of UW-Madison presentations 6ESA to feature wide range of UW-Madison presentations 7ESA to feature wide range of UW-Madison presentations 8Research exposes new target for malaria drugs 2
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Request Info...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Biology Products: